Australia's CSL rises after Jefferies sees plasma yield upside
BUZZ-Australia's CSL rises after Jefferies sees plasma yield upside ** Shares of Australia's CSL CSL.AX rise as much as 1.62% to A$184.4
** Jefferies says the biotechnology giant remains rated "hold", after its US plasma platform shift may lift efficiency but risks collection disruption
** Brokerage says CSL will replace Terumo systems with Haemonetics equipment across about 330 US centres by the end of 2027
** Jefferies notes channel checks suggest the new platform can deliver up to a 15% improvement in plasma collection yield
** Adds a single newer platform is aligned with CSL's cost-per-litre and gross margin goals, though benefits are likely to emerge gradually
** Jefferies says "the key risks are collection disruption during the changeover" and is watching for any disclosure of costs, savings and impairment
** Stock for the week up 5.1% and putting the stock on track for its best week in a month
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk;))
Recent news on CSL
See all newsAustralia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Sanofi avoids fine as EU accepts offer to stop disparaging rival vaccine (updated)